Wilson Sonsini Goodrich & Rosati represented Dewpoint Therapeutics in the transaction. Dewpoint Therapeutics Inc., the leading biotechnology company that develops therapeutics by targeting biomolecular condensates, announced...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati represented Saniona in the transaction. Saniona (OMX: SANION), a clinical-stage biopharmaceutical company, announced a partnership with Acadia Pharmaceuticals (Acadia) for the...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati represents Pacific Biosciences of California, Inc. on the transaction. Pacific Biosciences of California, Inc. (PacBio) (NASDAQ: PACB), a leading developer of...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Insider on the transaction. Insider, a leading AI-native omnichannel experience and customer engagement platform, announced raising $500 million in Series...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Stripe on the transaction. Financial infrastructure platform Stripe confirmed that it is acquiring stablecoin infrastructure provider Bridge. The transaction, which...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Terray on the transaction. Terray Therapeutics (Terray), a biotechnology company, announced raising $120 million in Series B funding round. The...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati represented Featurespace in the deal. Visa (NYSE: V) announced it has signed a definitive agreement to acquire Featurespace, a developer of...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Syxsense on the transaction. Absolute Security, announced it acquired Syxsense, a provider of automated endpoint and vulnerability management. Financial terms...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Borealis Biosciences on the transaction. Borealis Biosciences (Borealis), a next-generation RNA medicines company, emerged from stealth with $150 million in...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati represented DT Cloud Star Acquisition Corporation in the transaction, and Sichenzia Ross Ference Carmel represented A.G.P./Alliance Global Partners. DT Cloud Star...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Dren Bio on the transaction. Dren Bio, Inc., a privately held, clinical-stage biopharmaceutical company developing antibody therapeutics for cancer, autoimmune,...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati acted as Dida’s U.S. and Hong Kong counsel in the IPO and SEHK listing. China ride-sharing app operator Dida Inc. (Dida)...
You must be a Standard 1 Year member to access this content.
